BMO cuts rating on Merck and Biogen, on lack of near term catalyst

Investing.com12-20 22:44

Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to "market perform" from "outperform," citing concerns over its Gardasil franchise in China and uncertainty around filling...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492442404?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 22:44","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492442404","market":"us","top_or_hot":-1,"title":"BMO cuts rating on Merck and Biogen, on lack of near term catalyst","media":"Investing.com","content":"<div>\n<p>Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to \"market perform\" from \"outperform,\" citing concerns over its Gardasil franchise in China and uncertainty around filling...</p>\n\n<a href=\"https://finance.yahoo.com/news/bmo-cuts-rating-merck-biogen-144454558.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BMO cuts rating on Merck and Biogen, on lack of near term catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBMO cuts rating on Merck and Biogen, on lack of near term catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 22:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bmo-cuts-rating-merck-biogen-144454558.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to \"market perform\" from \"outperform,\" citing concerns over its Gardasil franchise in China and uncertainty around filling...</p>\n\n<a href=\"https://finance.yahoo.com/news/bmo-cuts-rating-merck-biogen-144454558.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://finance.yahoo.com/news/bmo-cuts-rating-merck-biogen-144454558.html","article_id":"2492442404","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492442404","pubTimestamp":1734705894,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com --BMO Capital Markets downgraded Merck &Company Inc  to \"market perform\" from \"outperform,\" citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.The brokerage lowered its price target on Merck  to $105 and flagged a lack of near-term catalysts, suggesting the stock may remain range-bound over the next year.BMO noted that the recent sell-off in Merck shares reflects growing skepticism in the pharmaceutical sector, with investors seeking more stable options. It added that while Merck has made progress in addressing post-2028 challenges, further clarity is needed to regain confidence.Additionally, brokerage also downgraded Biogen Inc  to \"market perform\" from \"outperform,\" on slower-than-expected revenue growth for Alzheimer's drug Leqembi, erosion in its multiple sclerosis business, and weaker growth in its rare disease portfolio.BMO noted management's efforts to ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司","BMO":"蒙特利尔银行","MRK":"默沙东"},"translate_title":"BMO因缺乏近期催化剂而下调默克和百健(Biogen)评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"BMO":1,"MRK":1},"content_text":"Investing.com -- BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to \"market perform\" from \"outperform,\" citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap as Keytruda faces loss of exclusivity and biosimilar competition.\nThe brokerage lowered its price target on Merck (NS:PROR) to $105 and flagged a lack of near-term catalysts, suggesting the stock may remain range-bound over the next year.\nBMO noted that the recent sell-off in Merck shares reflects growing skepticism in the pharmaceutical sector, with investors seeking more stable options. It added that while Merck has made progress in addressing post-2028 challenges, further clarity is needed to regain confidence.\nAdditionally, brokerage also downgraded Biogen Inc (NASDAQ:BIIB) to \"market perform\" from \"outperform,\" on slower-than-expected revenue growth for Alzheimer's drug Leqembi, erosion in its multiple sclerosis business, and weaker growth in its rare disease portfolio.\nThe brokerage cut its price target for Biogen to $164, noting limited near-term opportunities for high-value catalysts as the company works to address these challenges.\nBMO noted management's efforts to turn the business around, but it sees little upside for the stock in the near term as these issues are resolved.\nRelated Articles\nBMO cuts rating on Merck and Biogen, on lack of near term catalyst\nOhio senator-elect pushes for Stellantis to return Jeep, Ram, Dodge, and Chrysler to US control\nVivendi spinoffs, led by Canal+, lose value in first trading week post-breakup","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492442404"}